Ketamine for Sickle Cell Crisis

This trial explores whether a low dose of ketamine can effectively and safely reduce pain during sickle cell crises in children and young adults. Participants will receive either a low dose of ketamine (administered as a sub-dissociative infusion) alongside traditional pain medicine or only the traditional pain medicine. It targets individuals aged 5-20 with sickle cell disease who are currently experiencing pain crises requiring IV pain relief. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications. However, since the study involves adding ketamine to standard pain medicine, it's likely you can continue your current pain treatment.

Research has shown that using a low dose of ketamine is generally safe for treating pain during sickle cell crises. Studies indicate that, when combined with standard pain medicine like morphine, it can reduce the need for additional opioids. As a result, patients might experience less pain and require fewer doses of stronger drugs.

Unlike the standard of care for sickle cell crisis, which typically includes pain management with opioids and hydration, sub-dissociative ketamine works differently by targeting the NMDA receptors in the brain. This unique mechanism can provide pain relief without the heavy sedation and potential dependency linked to opioids. Researchers are excited about ketamine because it offers the potential for rapid pain relief and fewer side effects, which could significantly improve the quality of life for patients experiencing a sickle cell crisis.

Research has shown that a low dose of ketamine might help reduce pain for people with sickle cell disease during a pain crisis. In this trial, participants in one arm will receive a sub-dissociative ketamine infusion. Studies have found that combining ketamine with standard pain medicines like morphine often results in less pain for patients. Ketamine is also associated with a reduced need for opioids, potentially lowering the risk of side effects from these drugs. Some research suggests that ketamine's pain relief could be as effective as opioids. These findings indicate that ketamine could be a promising option for managing pain during sickle cell crises.¹²⁶⁷⁸